WGS
NASD GeneDx Holdings Corp. Class A$73.63 ↓ -2.16 (-2.85%) Trading Down from the previous close of $75.79, $2.18 below the day’s high of $75.81
- YTD change
- -43.39%
- vs 20-day SMA
- -17.58%
- vs 200-day SMA
- -7.49%
Price ranges
Price & Performance
+16.18 (+27.14%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 56.9% away from all-time highs of $170.87
- WGS is down 43% since the beginning of the year
- WGS is down 32% over the past 12 months
- WGS is down 13% over the past 1 month
- 39% of all WGS investors are betting against WGS
WGS reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -29.7%.
- Previous minute
- -$0.03
- Last hour
- -$0.01
- Last 5 days
- -18.91%
- vs 8-day SMA
- -17.45%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
GeneDx Holdings Corp. is a rare disease diagnosis company, with a mission to empower everyone to live their healthiest life through genomics. The firm combines clinical expertise, advanced technology, and the power of GeneDx Infinity. This foundation powers GeneDx's ExomeDx and GenomeDx tests, enabling clinicians to deliver precise, fast, and actionable diagnoses. The Infinity also fuels discovery for biopharma with AI-driven genomic intelligence. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.